Bayer HealthCare has joined the transparency movement. The drugmaker is the latest to announce that it, too, was making de-identified clinical trial information available to approved researchers. Boehringer Ingelheim announced a similar policy earlier this week.
Bayer said in a statement that its decision is in support of the European Medicines Agency’s efforts to increase access to clinical trial data, and noted that “as a member of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.”
As with BI, an independent panel will grant or deny data access.
